Morgan Stanley Downgrades Cytokinetics (CYTK) to Equalweight, 'approaching full valuation'
Tweet Send to a Friend
(Updated - January 5, 2024 4:07 AM EST)
Morgan Stanley analyst Jeffrey Hung downgraded Cytokinetics (NASDAQ: CYTK) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Morgan Stanley analyst Jeffrey Hung downgraded Cytokinetics (NASDAQ: CYTK) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
